Disparities in Diagnosis, Access to Specialist Care and Treatment for Inborn Errors of Immunity.

Journal: The journal of allergy and clinical immunology. In practice
Published Date:

Abstract

Inborn errors of immunity represent a rapidly expanding group of genetic disorders of the immune system. Significant advances have been made in recent years in diagnosis, including using genetic testing and newborn screening; treatment, including precision therapies, gene therapy and hematopoietic stem cell transplant; and development of patient registries to inform prevalence, understand morbidity of these disorders and guide the development of clinical trials. However, significant disparities due to age, race, ethnicity, socioeconomic status, or geographic location exist in all aspects of care of patients with inborn errors of immunity, beginning with delays in diagnosis and further compounded by impaired access to specialist care and treatment, leading to a notable impact on outcomes including morbidity and mortality. Addressing and correcting these disparities will require coordinated, deliberate and prolonged effort. Proposed strategies to improve equity at different levels include public health measures such as implementing universal newborn screening, supporting expanded health insurance coverage for diagnostic testing and treatment, improving access to novel therapeutics in low and middle income countries and developing artificial intelligence / machine learning tools to reduce delays in diagnosis, particularly in rural or less developed areas where access to specialist care is limited.

Authors

  • Monica G Lawrence
    University of Virginia School of Medicine, Department of Medicine, Division of Asthma, Allergy and Immunology, Charlottesville VA. Electronic address: Ml4nz@virginia.edu.
  • Nicholas L Rider
    Department of Health Systems & Implementation Science, Virginia Tech Carilion School of Medicine, Division of Allergy-Immunology Carilion Clinic, Roanoke, VA, United States.
  • Charlotte Cunningham-Rundles
    Division of Clinical Immunology, Icahn School of Medicine, Departments of Medicine and Pediatrics, Mount Sinai School of Medicine, New York, NY, United States.
  • M Cecilia Poli
    Program of Immunogenetics and Translational Immunology, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile; Hospital de niños Dr. Roberto del Rio, Santiago, Chile.

Keywords

No keywords available for this article.